Bisoprolol

Introduction Overview

Generic Name

bisoprolol

Brand Name

Zebeta

Dosage Form

Oral tablet

Drug Class

Cardioselective beta blockers

Pharmacokinetics

Absorption:
Bisoprolol is rapidly and almost completely absorbed after oral administration, with an absolute bioavailability of approximately 90%. Peak plasma concentrations are typically reached within 2 to 4 hours post-dose. Food does not significantly affect its absorption, thus bisoprolol can be taken with or without meals. The high and consistent bioavailability contributes to predictable pharmacokinetics, facilitating once-daily dosing in most patients.

Distribution:
Once absorbed, bisoprolol distributes extensively into body tissues with a volume of distribution ranging between 3 to 5 L/kg. It is moderately lipophilic and crosses biological membranes with ease. Plasma protein binding is around 30%, primarily to albumin. Bisoprolol’s cardioselectivity is associated with its affinity to beta-1 adrenergic receptors predominant in cardiac tissue, allowing targeted action with reduced effect on beta-2 receptors, which mediate bronchial and vascular smooth muscle effects.

Metabolism:
Bisoprolol undergoes limited hepatic metabolism involving cytochrome P450 isoenzymes, especially CYP3A4 and CYP2D6, converting a minor proportion into inactive metabolites. The low extent of hepatic metabolism accounts for its decreased potential for significant drug-drug interactions compared with other beta-blockers. Genetic polymorphisms affecting CYP2D6 may influence elimination half-life in some patients but are not generally clinically significant.

Elimination:
Bisoprolol has an elimination half-life of approximately 10 to 12 hours, enabling once-daily administration. It is excreted through both renal (about 50%) and fecal pathways as unchanged drug and metabolites. Renal clearance is the predominant route, and dose adjustments may be necessary in patients with moderate to severe renal impairment to avoid accumulation. Studies demonstrate steady-state plasma levels are typically achieved within 4 to 5 days of regular dosing, ensuring sustained beta-1 adrenergic blockade.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 2.5 mg, 5 mg, 10 mg

Dosages for Adults and Adolescents:
- Initial dose for hypertension: 5 mg orally once daily
- Dose titration: if target blood pressure is not achieved, increase to 10 mg once daily, then up to 20 mg once daily if necessary
- Some patients may benefit from a lower starting dose of 2.5 mg once daily, especially the elderly or those with comorbidities
- Maximum recommended dose: 20 mg daily

Specific Patient Populations:
- Dose adjustments may be necessary for patients with renal or hepatic impairment, though bisoprolol’s pharmacokinetics shows reduced hepatic metabolism
- It is not approved for use in individuals under 18 years old
- Caution and individualized dose titration are advised for patients with heart failure or conduction abnormalities, and careful monitoring is essential
- Elderly patients may require lower doses due to altered drug metabolism and increased drug sensitivity
- No formulation approved for intravenous use with Zebeta brand; only oral tablets available

Mechanism Of Action

Bisoprolol is a highly selective beta-1 adrenergic receptor antagonist, exerting its primary cardiovascular effects by blocking beta-1 receptors in cardiac tissue. This selective antagonism leads to a decreased response to sympathetic nervous system stimulation, resulting in a reduction in heart rate (negative chronotropic effect) and myocardial contractility (negative inotropic effect). The consequent lowering of cardiac output contributes to a reduction in systemic blood pressure, which is beneficial in the management of hypertension.

At the molecular level, bisoprolol competitively inhibits catecholamines such as norepinephrine and epinephrine from binding to beta-1 adrenergic receptors found predominantly in the heart. This blockade decreases cyclic AMP levels in myocardial cells through inhibition of adenylate cyclase activity, leading to diminished Ca2+ influx during the cardiac action potential. The reduction in intracellular calcium translates into lower myocardial oxygen consumption and decreased cardiac workload.

Bisoprolol's high cardioselectivity differentiates it from non-selective beta-blockers by minimizing blockade of beta-2 adrenergic receptors located in bronchial and vascular smooth muscle. This selectivity reduces the incidence of bronchoconstriction and peripheral vasoconstriction, making bisoprolol safer for patients with respiratory comorbidities such as asthma or mild chronic obstructive pulmonary disease (COPD). Clinical studies have demonstrated that bisoprolol maintains efficacy in lowering blood pressure and heart rate while providing a favorable safety and tolerability profile.

Additionally, by lowering heart rate and myocardial contractility, bisoprolol reduces arrhythmogenic potential by stabilizing cardiac electrical activity and decreasing oxygen demand. It has been shown to improve clinical outcomes in patients with hypertension and heart failure. Compared to other cardioselective beta-blockers, bisoprolol has a long half-life allowing convenient once-daily dosing and lower risk of central nervous system side effects due to its moderate lipophilicity. Overall, bisoprolol’s mechanism supports use in diverse cardiovascular indications requiring beta-1 adrenergic antagonism.

Pharmacological Actions

Selective beta-1 adrenergic receptor blockade leading to decreased heart rate and cardiac contractility
Reduction of cardiac output resulting in lowered systemic blood pressure
Decreased sympathetic nervous system activity on the heart, reducing myocardial oxygen consumption
Negative chronotropic and inotropic effects contributing to antiarrhythmic properties
Minimal beta-2 receptor blockade minimizing bronchoconstriction and peripheral vasoconstriction
Improvement in left ventricular function in appropriate heart failure patients
Reduction in renin release from juxtaglomerular cells of the kidney, contributing to antihypertensive effect
Antihypertensive effect achieved with once-daily dosing due to long plasma half-life
Cardioprotective effects via decreased myocardial workload and oxygen demand
Potential beneficial modulation of neurohormonal activation in heart failure
Favorable safety profile regarding respiratory side effects compared to non-selective beta-blockers
Lipid solubility allowing moderate blood-brain barrier penetration with limited CNS side effects
Decreased incidence of reflex tachycardia often seen with vasodilator antihypertensives
Dose-dependent efficacy with flexible titration for individualized blood pressure control
Helps prevent cardiac remodeling through modulation of sympathetic overactivation

Therapeutic Or Clinical Uses

Management of hypertension as monotherapy or in combination with other antihypertensive agents
Treatment of stable chronic heart failure (off-label use; more evidence needed specifically for bisoprolol)
Reduction of cardiovascular mortality and morbidity in hypertensive patients
Control of angina pectoris through decreased myocardial oxygen demand (off-label or class effect)
Heart rate control in atrial fibrillation and supraventricular tachycardia (off-label use)
Prevention of recurrent myocardial infarction and secondary prevention in ischemic heart disease (class effect)
Management of patients with tachyarrhythmias requiring beta-1 blockade
Reduction of renin secretion contributing to antihypertensive efficacy
Use in elderly hypertensive patients requiring careful dose titration
Adjunct therapy for reduction of cardiovascular risk factors associated with sympathetic overactivity
Improvement of exercise tolerance in patients with certain cardiac conditions (off-label)
Potential to reduce left ventricular hypertrophy associated with chronic hypertension
Treatment of mild to moderate hypertension not adequately controlled with lifestyle interventions
Suitable for patients with respiratory comorbidities due to cardioselectivity
Individualized therapy option in multi-drug regimens for resistant hypertension

Side Or Adverse Effects

Bradycardia (slow heart rate) sometimes requiring dose adjustment
Fatigue and weakness due to reduced cardiac output and peripheral perfusion
Headache and dizziness often correlating with blood pressure lowering effects
Sleep disturbances including insomnia and vivid dreams
Cold extremities, such as hands and feet, due to peripheral vasoconstriction
Gastrointestinal disturbances including nausea and diarrhea
Worsening of symptoms in patients with peripheral arterial disease or Raynaud’s phenomenon
Bronchospasm or wheezing in susceptible patients, although less common than with non-selective beta-blockers
Hypotension, particularly during dose initiation or dose escalation
Exacerbation of symptoms in patients with untreated asthma or chronic obstructive pulmonary disease
Fluid retention and peripheral edema reported rarely
Sexual dysfunction including decreased libido and erectile dysfunction
Depression and mood changes observed occasionally
Masking signs of hypoglycemia in diabetic patients, such as tachycardia
Allergic reactions including rash, pruritus, or rarely severe hypersensitivity

Precautions

Avoid abrupt discontinuation to prevent exacerbation of angina, myocardial infarction, or arrhythmias
Use caution in patients with conduction abnormalities such as sinoatrial or AV block without pacemaker
Monitor for bradycardia and hypotension during dose initiation and titration
Exercise caution in patients with bronchospastic diseases despite cardioselectivity
Monitor blood glucose closely in diabetic patients, as bisoprolol may mask hypoglycemia symptoms
Adjust dosage in patients with impaired hepatic or renal function
Assess for signs of heart failure worsening in patients with known cardiac disease
Evaluate concomitant use with other negative chronotropic or hypotensive agents to avoid additive effects
Inform patients about potential fatigue and impairments in concentration or alertness
Use in pregnancy only if clearly needed, considering potential fetal risks
Breastfeeding mothers should use caution, considering unknown excretion in human milk
Avoid use in patients with severe peripheral arterial disease to prevent worsening symptoms
Advise patients to rise slowly from sitting or lying positions to reduce orthostatic hypotension risk
Instruct patients to report any signs of allergic reactions promptly
Ensure clinicians are informed prior to surgery to manage perioperative beta-blocker therapy appropriately

Warnings

Do not discontinue therapy abruptly due to risk of rebound hypertension, myocardial ischemia, or arrhythmias
Contraindicated in patients with severe bradycardia and advanced AV block without pacemaker
Potential for severe hypotension and bradyarrhythmias requiring emergency intervention
Use with caution in patients with heart failure as it may exacerbate symptoms if not carefully managed
May mask clinical signs of hyperthyroidism or hypoglycemia
Risk of bronchospasm even though bisoprolol is cardioselective, especially in patients with reactive airway disease
Patients undergoing surgery must inform anesthesiologists about bisoprolol use due to potential interactions
Can cause severe allergic reactions; discontinue immediately if anaphylaxis occurs
Avoid alcohol consumption as it may potentiate hypotensive side effects
Use caution in patients with peripheral vascular disease to avoid worsening limb ischemia
Monitor closely the first weeks of therapy due to potential for serious adverse cardiac events
Do not use in patients with decompensated heart failure requiring intravenous inotropes
Avoid use in patients with sick sinus syndrome without pacemaker
May lead to depression or mood alterations necessitating psychiatric evaluation
Warn that fatigue or dizziness may impair ability to operate machinery or drive

Contraindication

Known hypersensitivity or allergy to bisoprolol or other beta-blockers
Second or third-degree atrioventricular (AV) block without a pacemaker
Severe bradycardia (less than 45 beats per minute)
Cardiogenic shock or decompensated heart failure requiring intravenous inotropes
Severe peripheral arterial circulatory disorders
Sick sinus syndrome without pacemaker
Severe asthma or chronic obstructive pulmonary disease with bronchospasm
Untreated phaeochromocytoma without alpha-blockade
Severe hypotension (systolic blood pressure below 90 mmHg)
Known sinoatrial node dysfunction
Metabolic acidosis
Acute heart failure or pulmonary edema
Patients experiencing cardiogenic shock
Hypersensitivity to any components of the drug formulation
Use in pediatric patients under 18 years of age (not approved)

Drug Interactions

Additive bradycardia and atrioventricular block when combined with calcium channel blockers such as verapamil and diltiazem
Enhanced hypotensive effect when used concomitantly with other antihypertensives including clonidine and reserpine
Potential decreased efficacy when administered with rifampin due to increased metabolism of bisoprolol
Risk of hypoglycemia masking when combined with insulin or oral hypoglycemic agents; careful glucose monitoring required
Additive negative chronotropic effects with digoxin leading to profound bradycardia or heart block
Increased risk of hypotension and bradycardia with other beta-blockers or antiarrhythmics
Concomitant use with NSAIDs may reduce antihypertensive efficacy of bisoprolol
Use with anesthetic agents may potentiate cardiovascular depression, requiring monitoring during surgery
Beta-2 receptor inhibition may be potentiated if used simultaneously with non-selective beta-blockers leading to bronchospasm
Potentiation of effects when combined with centrally acting sympatholytics
Concurrent use with drugs that prolong QT interval requires caution due to arrhythmia risk
May interfere with response to epinephrine during anaphylactic reactions
Caution with use of CYP2D6 inhibitors as they may increase bisoprolol plasma levels
Careful supervision when combined with diuretics to prevent excessive hypotension
Potential pharmacodynamic interactions with antidepressants, especially tricyclics and MAO inhibitors

Preparations Of The Drug

Oral tablets available in 2.5 mg strength under the generic name bisoprolol
Oral tablets available in 5 mg strength as branded Zebeta and generic bisoprolol
Oral tablets available in 10 mg strength for titration and maintenance therapy
Tablets manufactured with excipients to ensure adequate stability and shelf-life at room temperature
Packaging includes blister packs and bottles with child-resistant caps to ensure safety
No sustained-release or extended-release formulations in the Zebeta brand; immediate-release tablets predominately used
Generics available with equivalent bioavailability following FDA approval of bioequivalence studies
Storage recommended at controlled room temperature away from moisture and excessive heat
Available as monotherapy oral tablets; no combination products containing bisoprolol and other agents marketed under Zebeta
Manufactured under Good Manufacturing Practices (GMP) ensuring quality, purity, and potency
Prescribed exclusively for oral administration; no injectable forms under Zebeta brand
Recently discontinued Zebeta brand in the U.S.; healthcare providers typically utilize generic bisoprolol formulations
Manufacturer labeling provides detailed information on dosing instructions, contraindications, and side effects
Imaging and identification guides available for tablets to aid in verification and avoid dispensing errors
Produced by multiple pharmaceutical companies globally ensuring wide availability of generic bisoprolol